EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Exposure–Response Relationships in Patients with Non‐Small‐Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3‐DXd)

Li Li iD, Mark Lee, Rujuta Joshi, Yuan Xu iD, Ramon Garcia, Kyle Baron iD, Eric Anderson iD, Tim Waterhouse iD, David Sternberg, Pomy Shrestha, Pavan Vaddady iD, Malaz Abutarif und 1 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3674 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Li Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Receptor, ErbB-3, Camptothecin. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patritumab deruxtecan (HER3‐DXd, also known as MK‐1022), an antibody‐drug conjugate consisting of a human epidermal growth factor receptor 3 (HER3) antibody attached to a topoisomerase I inhibitor payload (DXd), has demonstrated efficacy in patients with metastatic breast cancer and non‐small cell lung cancer (NSCLC). Exposure–efficacy was assessed in 446 patients with EGFR ‐mutated NSCLC; exposure–safety was assessed in 715 patients with NSCLC, breast cancer, or colorectal cancer. A range of HER3‐DXd dosing regimens was evaluated, including fixed‐dosing regimens (1.6–8 mg/kg every 3 weeks [Q3W]; 3.2–6.4 mg/kg Q3W), an up‐titration dosing regimen, and an alternative Q2W/Q3W dosing regimen. Logistic regression or time‐to‐event models were used to test the relationships of each endpoint with pharmacokinetic analytes (anti‐HER3‐ac‐DXd and DXd). Anti‐HER3‐ac‐DXd exposure was positively associated with objective response rate, and bone metastasis was identified as a significant covariate. DXd exposure showed a stronger correlation with most safety endpoints compared with anti‐HER3‐ac‐DXd exposure, except for grade ≥ 2 nausea/vomiting and any grade adjudicated drug‐related interstitial lung disease (ILD). Dose response predictions verified a manageable safety profile for the 5.6 mg/kg Q3W regimen. This observation was supported by low predicted rates of adjudicated drug‐related ILD and adverse events leading to treatment discontinuation with the 5.6 mg/kg Q3W regimen. Overall, these results support the selection of HER3‐DXd 5.6 mg/kg Q3W as the recommended dosing regimen for patients with NSCLC, and these data inform the optimal dosing regimen for other tumor types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsReceptor, ErbB-3CamptothecinImmunoconjugatesAntibodies, MonoclonalHumansFemaleMaleMiddle AgedAntibodies, Monoclonal, HumanizedAgedDose-Response Relationship, DrugAdultAged, 80 and overBroadly Neutralizing AntibodiesTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedpatritumabReceptor, ErbB-3CamptothecinImmunoconjugatesERBB3 protein, humanAntibodies, MonoclonalBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.
  • Metrum Research Group, Tariffville, Connecticut, USA.

ORCID-Profile: Li Li, Yuan Xu, Kyle Baron, Eric Anderson, Tim Waterhouse, Pavan Vaddady

Zitieren

APA

Li, L., Lee, M., Joshi, R., Xu, Y., Garcia, R., Baron, K., Anderson, E., Waterhouse, T., Sternberg, D., Shrestha, P., Vaddady, P., Abutarif, M., & Garimella, T. (2025). Exposure–Response Relationships in Patients with Non‐Small‐Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3‐DXd). Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3674

Vancouver

Li L, Lee M, Joshi R, Xu Y, Garcia R, Baron K, et al. Exposure–Response Relationships in Patients with Non‐Small‐Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3‐DXd). Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3674

BibTeX
@article{Li2025,
  author = {Li, Li and Lee, Mark and Joshi, Rujuta and Xu, Yuan and Garcia, Ramon and Baron, Kyle and Anderson, Eric and Waterhouse, Tim and Sternberg, David and Shrestha, Pomy and Vaddady, Pavan and Abutarif, Malaz and Garimella, Tushar},
  title = {Exposure–Response Relationships in Patients with Non‐Small‐Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3‐DXd)},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3674}
}
Kostenlos starten →